Novo Nordisk
Novo Nordisk creates four senior vice presidents
February 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk
Novo Nordisk has promoted four corporate vice presidents within its ranks into senior vice presidents. The following members of the US …
EU approval for Novo Nordisk diabetes drugs
January 24, 2013Sales and Marketing Novo Nordisk, Ryzodeg, Tresiba
Novo Nordisk is celebrating after European regulators approved two of its drugs for the treatment of adults with diabetes. The …
Novo Nordisk appoints Curtis Oltmans to US executive team
January 8, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Oltmans
Novo Nordisk has announced that Curtis Oltmans has been promoted to corporate vice president and general counsel, Legal and Quality …
European green light for Novo’s Tresiba
October 24, 2012Sales and Marketing EMA, Novo Nordisk, Tresiba
The European Medicines Agency has given the go-ahead for Novo Nordisk’s Tresiba, a new basal analogue insulin to treat diabetes …
Novo Nordisk to expand Beijing R&D centre
September 25, 2012Research and Development, Sales and Marketing Beijing, China, Novo Nordisk, R&D
Novo Nordisk is investing $100 million into enlarging its R&D facilities in Beijing into a state-of-the-art centre. Located in the …
BMJ: diabetes post-marketing studies used to boost sales
June 14, 2012Sales and Marketing BMJ, Edwin Gale, Novo Nordisk, post-marketing
The use of post-marketing studies for diabetes is being used to sell more medicines rather than for science, according to …
Positive data for Sanofi’s diabetes drug
June 13, 2012Research and Development, Sales and Marketing Lyxumia, Novo Nordisk, Sanofi, Victoza, diabetes
Sanofi’s new diabetes treatment Lyxumia has significantly reduced glycated hemoglobin (HbA1c) in two late-stage trials, the manufacturer says. Paris-based Sanofi …
Novo Nordisk appoints ex-Pfizer head
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Pfizer, Robert Clark, regulatory affairs
Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs. Clark will lead Novo Nordisk’s US regulatory team, …
Victoza superiority to Januvia made official by FDA
April 10, 2012Medical Communications, Sales and Marketing Januvia, Merck, Novo Nordisk, Victoza, diabetes
Novo Nordisk is now able to claim superiority for its diabetes drug Victoza compared to Merck’s rival treatment Januvia.The US …
Diabetes – the battle for control
February 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Novo Nordisk, Sanofi, Victoza, degludec, diabetes
This year marks the 90th anniversary of the first ever successful use of insulin to treat patients with type I …
Study supports GLP-1 agonists for weight loss
January 10, 2012Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly
An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …
AstraZeneca, Novo and Enlight sign collaborative research deal
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, Enlight, Novo Nordisk
AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …
Novo confident on ultra-long acting insulin
December 8, 2011Sales and Marketing Novo Nordisk, diabetes, insulin
Novo Nordisk says a new combination of a long-acting insulin with a short-acting insulin helps patients maintain better control of …
Novo Nordisk sponsors haemophilia comic
October 7, 2011Medical Communications Novo Nordisk, haemophilia, medical communications news
Novo Nordisk is sponsoring an educational comic about haemophilia for young sufferers of the blood disorder in the UK. It …
Fresh scrutiny for new diabetes drugs
September 15, 2011Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
